Sanctuary Advisors LLC Has $68.92 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Sanctuary Advisors LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 444,179 shares of the company's stock after selling 13,009 shares during the period. Sanctuary Advisors LLC's holdings in Johnson & Johnson were worth $68,923,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Vinva Investment Management Ltd increased its stake in shares of Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after purchasing an additional 7,110 shares during the period. Financial Counselors Inc. lifted its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after buying an additional 9,309 shares during the last quarter. Meridian Financial Partners LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $1,626,000. Meridian Investment Counsel Inc. raised its stake in Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after purchasing an additional 3,710 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after purchasing an additional 102,502 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE JNJ traded down $0.41 during mid-day trading on Thursday, hitting $146.23. The company's stock had a trading volume of 6,174,458 shares, compared to its average volume of 7,118,662. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a market cap of $352.07 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.51. The company's fifty day simple moving average is $157.29 and its 200-day simple moving average is $156.35. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson's payout ratio is 71.78%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on JNJ shares. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price for the company. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 16th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.73.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.